

MEDAREX INC  
Form 8-K  
March 31, 2006

**As filed with the Securities and Exchange Commission on March 31, 2006.**

## **SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549



**FORM 8-K**

**CURRENT REPORT**



Edgar Filing: MEDAREX INC - Form 8-K

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)**

**March 31, 2006 (March 31, 2006)**

---

**MEDAREX, INC.**

(Exact name of registrant as specified in its charter)

**New Jersey**  
(State of other jurisdiction of  
incorporation)

**0-19312**  
(Commission File Number)

**22-2822175**  
(IRS Employer  
Identification No.)

**707 State Road, Princeton, N.J. 08540-1437**

Edgar Filing: MEDAREX INC - Form 8-K

(Address of Principal Executive Offices)

Registrant's telephone number, including area code: **(609) 430-2880**

**Not Applicable**



Edgar Filing: MEDAREX INC - Form 8-K

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
  
  - o Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

*MEDAREX, INC.*

*TABLE OF CONTENTS*

*FOR*

*CURRENT REPORT ON FORM 8-K*

Item 8.01

Other Events



Item 9.01      Financial Statements and Exhibits



Signature

**Item 8.01. Other Events.**

On March 31, 2006, Medarex, Inc. issued a press release announcing the initiation of a registrational clinical trial studying ipilimumab (also known as MDX-010) as a monotherapy in previously-treated metastatic melanoma patients. Medarex is developing ipilimumab in collaboration with Bristol-Myers Squibb Company.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

**Exhibit  
Number**

99.1 Medarex, Inc. Press Release dated March 31, 2006.

*SIGNATURE*

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDAREX, INC.  
Registrant

Date: March 31, 2006

By: /s/ Christian S. Schade  
Christian S. Schade  
Senior Vice President and Chief  
Financial Officer



**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>	<b>Page Number</b>
99.1	Medarex, Inc. Press Release dated March 31, 2006.	